Extended Release Tacrolimus (Advagraf®) in Severe Adult Atopic Dermatitis Patients

U

UMC Utrecht

Status

Completed

Conditions

Atopic Dermatitis

Treatments

Drug: Extended release tacrolimus (Advagraf®)

Study type

Observational

Funder types

Other

Identifier

NCT01789619

Details and patient eligibility

About

To evaluate the clinical efficacy of the extended release formulation of tacrolimus (Advagraf®) in patients with severe atopic dermatitis, who can not be treated adequately with cyclosporine A because of side effects and/or non-responsiveness.

Enrollment

9 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult patients with severe atopic dermatitis, uncontrolled by topical treatment (indication for oral immunosuppressive drugs), who are unresponsive to Cyclosporin A, or in which treatment was discontinued because of side effects.

Exclusion criteria

  • Concomitant use of other oral immunosuppressive drugs and/or UV light therapy
  • Preexisting abnormalities in liver function, kidney function or haematological abnormalities
  • History of malignancy within the last 5 years
  • Uncontrolled hypertension
  • Pregnancy or lactation; wish for pregnancy during the treatment period
  • Infections requiring continued therapy
  • Known positivity for HIV
  • Evidence of drug and/or alcohol abuse

Trial design

9 participants in 1 patient group

Extended release tacrolimus (Advagraf®)
Treatment:
Drug: Extended release tacrolimus (Advagraf®)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems